Gene editing shown to prevent open angle glaucoma.

The results of a 24-year collaborative study was published last week in PNAS.
What are the talking points? 
Myocilin and CRISPR-Cas9 (stay with me).
Myocilin is a protein found in the trabecular meshwork and it has long been established that a mutation in this protein causes elevated IOP.
In this study, scientists found that editing the gene that makes this protein using a method called CRISPR-Cas9, prevented glaucoma in mice.
Why is the research community freaking out about CRISPR-Cas9?
Because it carries the potential to edit genes in humans and prevent a disease, all non-invasively.
(For a great animation on how CRSIPR-Cas9 works, watch this.)
The authors say this could translate into a new therapy for treating open angle glaucoma. The more we know, the closer we get to eliminating the disease. (via)

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.

Related Articles

Latest Posts